Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index, and 1 are not checked yet.

Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective

Open access
Hertzberg, Silvia Nanjala Walekhwa, Jørstad, Øystein K., Petrovski, Beáta Éva, Bragadottir, Ragnheidur, Steffensen, Leif Arthur, Moe, Morten Carstens, Burger, Emily A., Petrovski, Goran · 2022 · International Journal of Environmental Research and Public Health

Abstract

Purpose: To describe the trends in hospital utilization and economic outcomes associated with the transition from laser to intravitreal injection (IVI) therapy for diabetic retinopathy (DR) at Oslo University Hospital (OUH), which provides the largest retina service in Norway. Methods: This descriptive study analyzed hospital administrative data and determined the average utilization and treatment proportions of laser therapy, IVIs and vitrectomy for each patient per year. The Chi-square test was used to compare resource use between treatment groups. From an extended healthcare perspective, the annual cost per patient was calculated using Norwegian tariff data from 2020 and the National Medication Price Registry for patients seen between 2010 and 2018. Bootstrapping was performed to generate 95% confidence intervals for the cost per patient per year. Results: Among the 1838 (41% female) patients treated for DR between 2005 and 2018, OUH provided on average 1.09 laser treatments per DR patient and 0.54 vitrectomies per DR patient in 2005, whose utilization declined to 0.54 and 0.05 treatments per DR patient, respectively, by 2018. Laser treatments declined from 64% to 10%, while vitrectomies declined from 32% to 1%. In contrast, IVI treatments increased from 4.5% to 89% of the total share, representing an average increase, from 0.08 injections per patient in 2005 to 4.73 injections per patient in 2018. Both the increasing number of DR patients and the shift in the type of treatment increased the economic costs of treating DR from a total of EUR 0.605 million (EUR 2935 per patient) in 2010 to EUR 2.240 million (EUR 3665 per patient) in 2018, with IVIs contributing considerably to these costs. Conclusions: Despite the decline in the use of vitrectomies, the transition from laser to IVI therapy for DR increased the healthcare resource utilization and economic costs of its treatment over the observed time. A main cost driver was the need for long-term IVIs, in addition to the drug cost itself. Trade-offs can be achieved through effective alternative IVI delivery or appropriate drug choice that balances patient needs with the economic burden of treating DR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijerph191912603

Cites

51 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure A1 Number of treated patients per year receiving intravitreal injection, laser or vitreoretinal surgery (2005–2018).
Figure A1 Number of treated patients per year receiving intravitreal injection, laser or vitreoretinal surgery (2005–2018).CC BY · PubMed Central
Figure A2 Percentage of the number of patients with diabetic retinopathy being treated with the different treatment modalities per year.
Figure A2 Percentage of the number of patients with diabetic retinopathy being treated with the different treatment modalities per year.CC BY · PubMed Central
Figure A3 Vitreoretinal surgery procedures performed on patients who did not receive any other treatment for diabetic retinopathy at Oslo University Hospital. Among those who received vitreoretinal surgery, there was an increasing trend for patients who were treated with surgery alone; in this patient group, however, the hospital service area was wider than for those receiving intravitreal injections and laser only.
Figure A3 Vitreoretinal surgery procedures performed on patients who did not receive any other treatment for diabetic retinopathy at Oslo University Hospital. Among those who received vitreoretinal surgery, there was an increasing trend for patients who were treated with surgery alone; in this patient group, however, the hospital service area was wider than for those receiving intravitreal injections and laser only.CC BY · PubMed Central
Figure 1 The annual number of new patients and those being treated the previous year, discharged patients, and patients in total.
Figure 1 The annual number of new patients and those being treated the previous year, discharged patients, and patients in total.CC BY · PubMed Central
Figure 2 Average percentage of treatments for diabetic retinopathy in patients receiving laser, intravitreal injection and/or vitreoretinal surgery.
Figure 2 Average percentage of treatments for diabetic retinopathy in patients receiving laser, intravitreal injection and/or vitreoretinal surgery.CC BY · PubMed Central
Figure 3 Annual total healthcare cost of treating diabetic retinopathy per modality and total treatment costs.
Figure 3 Annual total healthcare cost of treating diabetic retinopathy per modality and total treatment costs.CC BY · PubMed Central
Figure 4 Total costs per year of each intravitreal drug (A) and percentage of the total cost per year for each of those drugs (B).
Figure 4 Total costs per year of each intravitreal drug (A) and percentage of the total cost per year for each of those drugs (B).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 3

  1. European Society of Cardiology (ESC) Global Statistics on Diabetes, ESC Press Office. Available online: https://www.escardio.org/Education/Diabetes-and-CVD/Recommended-Reading/global-statistics-on-diabetes.
  2. Singer, 2012, Effect of Combination Therapy with Bevacizumab and Dexamethasone Intravitreal Implant in Patients with Retinal Vein Occlusion, Retina, 32, 1289
  3. Haas, M., and Hall, J. (2015). The Economic Evaluation of Health Care, Oxford University Press.

Cited by

See all 6

Metadata

Authors
Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G.
Affiliations
  • University of Oslo (NO)
  • Oslo University Hospital (NO)
  • Center for Eye Research, Department of Ophthalmology, Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway
  • Harvard University (US)
Corresponding author
Petrovski, Goran
Venue
International Journal of Environmental Research and Public Health
Publisher
MDPI AG
Published
2022-10-02
Volume
19
Issue
19
Pages
12603
ISSN
1660-4601 (ISSN-L)
OpenAlex
W4303696557
Cited by
6
References
51
Citations by year
2025: 3 · 2024: 1 · 2023: 2
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
Funders
Baltic Research Programme of the European Economic Area (EEZ/BPP/VIAA/2021/8)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
diabetic retinopathy, intravitreal injection, laser photocoagulation, vitrectomy, hospital utilization, health care costs, treatment trends, cost drivers, drug costs, retinal disease management, Norway, Oslo University Hospital, cost-effectiveness trade-off, drug selection, quality of life
MeSH terms
Delivery of Health Care, Diabetes Mellitus, Diabetic Retinopathy, Female, Hospitals, Humans, Lasers, Male, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective. https://app.cochat.ai/papers/10.3390/ijerph191912603
The paper
Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G. (2022). Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph191912603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.